Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exosome shots outperform minoxidil for baldness?

NCT ID NCT07776015

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether intradermal injections of exosomes—tiny particles that help cells communicate—can regrow hair in people with androgenetic alopecia (common pattern baldness) better than the standard topical minoxidil treatment. Forty participants will receive either exosome injections or minoxidil for three months, with doctors evaluating hair improvement using a global scale and safety monitoring. The goal is to see if this novel approach offers a more effective or convenient alternative for hair loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intradermal injections of exosomes (Exomide) compared with 5% topical minoxidil solution
What this could lead to
If exosome injections prove effective, they could offer a new, non-surgical option for treating common pattern hair loss, potentially with better results than standard topical treatments.
What could go wrong
This is a small, early-stage trial with only 40 participants, so results may not apply broadly. Exosome injections carry risks like injection-site reactions, and their long-term safety and effectiveness are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Apr 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Were male or female patients with a confirmed diagnosis of androgenetic alopecia (AGA). Had not received any treatment for AGA for at least 6 months before study initiation. Provided written informed consent. Agreed to attend the scheduled follow-up assessments and undergo photographic documentation. Exclusion Criteria: * Concurrent scalp diseases. A history of bleeding disorders. Current use of anticoagulant medications. Known keloidal tendency. History of psoriasis or lichen planus. Significant cardiac, hepatic, or renal disease. Any major systemic illness. Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenetic alopecia Exosomes

Contacts and locations

Locations

  • Tanta University Hospitals

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.